2023
The Cooperative Re-Engagement Controlled Trial (CoRECT): Durable Viral Suppression Assessment
O'Shea J, Fanfair R, Williams T, Khalil G, Brady K, DeMaria A, Villanueva M, Randall L, Jenkins H, Altice F, Camp N, Lucas C, Buchelli M, Samandari T, Weidle P. The Cooperative Re-Engagement Controlled Trial (CoRECT): Durable Viral Suppression Assessment. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2023, 93: 134-142. PMID: 36812382, PMCID: PMC10962216, DOI: 10.1097/qai.0000000000003178.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Retroviral AgentsFemaleHIV InfectionsHumansMassachusettsParturitionPregnancyProspective StudiesViral LoadConceptsDurable viral suppressionActive public health interventionProportion of PWHPublic health interventionsViral loadCare strategiesHealth interventionsLast viral loadCopies/mLStandard of careRace/ethnicityCare armHIV careViral suppressionAntiretroviral adherenceCD4 categoryExposure categoriesCare individualsPWHCareAge categoriesInterventionTrialsBirth sexRe-Engagement
2021
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
Domingo P, Mur I, Mateo G, Gutierrez M, Pomar V, de Benito N, Corbacho N, Herrera S, Millan L, Muñoz J, Malouf J, Molas M, Asensi V, Horcajada J, Estrada V, Gutierrez F, Torres F, Perez-Molina J, Fortun J, Villar L, Hohenthal U, Marttila H, Vuorinen T, Nordberg M, Valtonen M, Frigault M, Mansour M, Patel N, Fernandes A, Harvey L, Foulkes A, Healy B, Shah R, Bensaci A, Woolley A, Nikiforow S, Lin N, Sagar M, Shrager H, Huckins D, Axelrod M, Pincus M, Fleisher J, Lampa J, Nowak P, Vesterbacka J, Rasmuson J, Skorup P, Janols H, Niward K, Chatzidionysiou K, Asgeirsson H, Parke Å, Blennow O, Svensson A, Aleman S, Sönnerborg A, Henter J, Horne A, Al-Beidh F, Angus D, Annane D, Arabi Y, Beane A, Berry S, Bhimani Z, Bonten M, Bradbury C, Brunkhorst F, Buxton M, Cheng A, Cove M, De Jong M, Derde L, Estcourt L, Goossens H, Gordon A, Green C, Haniffa R, Ichihara N, Lamontagne F, Lawler P, Litton E, Marshall J, McArthur C, McAuley D, McGuinness S, McVerry B, Montgommery S, Mouncey P, Murthy S, Nichol A, Parke R, Parker J, Reyes F, Rowan K, Saito H, Santos M, Seymour C, Shankar-Hari M, Turgeon A, Turner A, van Bentum-Puijk W, van de Veerdonk F, Webb S, Zarychanski R, Baillie J, Beasley R, Cooper N, Fowler R, Galea J, Hills T, King A, Morpeth S, Netea M, Ogungbenro K, Pettila V, Tong S, Uyeki T, Youngstein T, Higgins A, Lorenzi E, Berry L, Salama C, Rosas I, Ruiz-Antorán B, Muñez Rubio E, Ramos Martínez A, Campos Esteban J, Avendaño Solá C, Pizov R, Sanz Sanz J, Abad-Santos F, Bautista-Hernández A, García-Fraile L, Barrios A, Gutiérrez Liarte Á, Alonso Pérez T, Rodríguez-García S, Mejía-Abril G, Prieto J, Leon R, VEIGA V, SCHEINBERG P, FARIAS D, PRATS J, CAVALCANTI A, MACHADO F, ROSA R, BERWANGER O, AZEVEDO L, LOPES R, DOURADO L, CASTRO C, ZAMPIERI F, AVEZUM A, LISBOA T, ROJAS S, COELHO J, LEITE R, CARVALHO J, ANDRADE L, SANDES A, PINTÃO M, SANTOS S, ALMEIDA T, COSTA A, GEBARA O, FREITAS F, PACHECO E, MACHADO D, MARTIN J, CONCEIÇÃO F, SIQUEIRA S, DAMIANI L, ISHIHARA L, SCHNEIDER D, DE SOUZA D, Hermine O, Mariette X, Tharaux P, Resche Rigon M, Porcher R, Ravaud P, Azoulay E, Cadranel J, Emmerich J, Fartoukh M, Guidet B, Humbert M, Lacombe K, Mahevas M, Pene F, Pourchet-Martinez V, Schlemmer F, Tibi A, Yazdanpanah Y, Dougados M, Bureau S, Horby P, Landray M, Baillie K, Buch M, Chappell L, Day J, Faust S, Haynes R, Jaki T, Jeffery K, Juszczak E, Lim W, Mafham M, Montgomery A, Mumford A, Thwaites G, Kamarulzaman A, Syed Omar S, Ponnampalavanar S, Raja Azwa R, Wong P, Kukreja A, Ong H, Sulaiman H, Basri S, Ng R, Megat Johari B, Rajasuriar R, Chong M, Neelamegam M, Syed Mansor S, Zulhaimi N, Lee C, Altice F, Price C, Malinis M, Hasan M, Wong C, Chidambaram S, Misnan N, Mohd Thabit A, Sim B, Bidin F, Mohd Abd Rahim M, Saravanamuttu S, Tuang W, Mohamed Gani Y, Thangavelu S, Tay K, Ibrahim N, Halid L, Tan K, Mukri M, Arip M, Koh H, Syed Badaruddin S, Raja Sureja L, Chun G, TORRE-CISNEROS J, MERCHANTE N, LEON R, CARCEL S, GARRIDO J, Galun E, Soriano A, Martínez J, Castán C, Paredes R, Dalmau D, Carbonell C, Espinosa G, Castro P, Muñóz J, Almuedo A, Prieto S, Pacheco I, Ratain M, Pisano J, Strek M, Adegunsoye A, Karrison T, Jozefien D, Karel F.A. V, Elisabeth D, Cedric B, Bastiaan M, Shankar-Hari M, Vale C, Godolphin P, Fisher D, Higgins J, Spiga F, Savovic J, Tierney J, Baron G, Benbenishty J, Berry L, Broman N, Cavalcanti A, Colman R, De Buyser S, Derde L, Domingo P, Omar S, Fernandez-Cruz A, Feuth T, Garcia F, Garcia-Vicuna R, Gonzalez-Alvaro I, Gordon A, Haynes R, Hermine O, Horby P, Horick N, Kumar K, Lambrecht B, Landray M, Leal L, Lederer D, Lorenzi E, Mariette X, Merchante N, Misnan N, Mohan S, Nivens M, Oksi J, Perez-Molina J, Pizov R, Porcher R, Postma S, Rajasuriar R, Ramanan A, Ravaud P, Reid P, Rutgers A, Sancho-Lopez A, Seto T, Sivapalasingam S, Soin A, Staplin N, Stone J, Strohbehn G, Sunden-Cullberg J, Torre-Cisneros J, Tsai L, van Hoogstraten H, van Meerten T, Veiga V, Westerweel P, Murthy S, Diaz J, Marshall J, Sterne J. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. JAMA 2021, 326: 499-518. PMID: 34228774, PMCID: PMC8261689, DOI: 10.1001/jama.2021.11330.Peer-Reviewed Original ResearchConceptsIL-6 antagonistsUsual careCause mortalitySummary odds ratiosOdds ratioEligible trialsMechanical ventilationClinical trialsMortality riskSecondary infectionCOVID-19Primary outcome measureAbsolute mortality riskBias assessment toolRisk of biasStudy selection criteriaCochrane riskSecondary outcomesI2 statisticPlaceboOutcome measuresMAIN OUTCOMEPatientsAdditional trialsPrimary analysis
2018
Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community
Springer SA, Di Paola A, Azar M, Barbour R, Biondi BE, Desabrais M, Lincoln T, Skiest DJ, Altice FL. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 78: 43-53. PMID: 29373393, PMCID: PMC5889326, DOI: 10.1097/qai.0000000000001634.Peer-Reviewed Original ResearchMeSH KeywordsAdultCriminal LawDelayed-Action PreparationsDouble-Blind MethodFemaleFollow-Up StudiesHIV InfectionsHIV-1HumansInjections, IntramuscularMaleMiddle AgedMultivariate AnalysisNaltrexoneNarcotic AntagonistsOpioid-Related DisordersPrisonersProspective StudiesResearch DesignRNA, ViralTime FactorsTreatment OutcomeViral LoadConceptsOpioid use disorderViral suppressionXR-NTXPlacebo groupPrimary outcomeUse disordersXR-NTX groupPlacebo-controlled trialExtended-release naltrexoneStatistical significant differenceRelease naltrexoneMonthly injectionsEligible participantsTreatment groupsJail detaineesHIVMonthsBaselinePlaceboSignificant differencesNaltrexoneJail inmatesDisordersVS levelsOutcomesIntegrated Bio-behavioral Approach to Improve Adherence to Pre-exposure Prophylaxis and Reduce HIV Risk in People Who Use Drugs: A Pilot Feasibility Study
Shrestha R, Altice FL, Karki P, Copenhaver MM. Integrated Bio-behavioral Approach to Improve Adherence to Pre-exposure Prophylaxis and Reduce HIV Risk in People Who Use Drugs: A Pilot Feasibility Study. AIDS And Behavior 2018, 22: 2640-2649. PMID: 29582199, PMCID: PMC6051885, DOI: 10.1007/s10461-018-2099-0.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnalgesics, OpioidBiobehavioral SciencesCondomsFeasibility StudiesFemaleHIV InfectionsHumansMaleMedication AdherenceMethadoneMiddle AgedMotivationOpiate Substitution TreatmentOpioid-Related DisordersPatient Acceptance of Health CarePilot ProjectsPre-Exposure ProphylaxisProspective StudiesRisk Reduction BehaviorSexual BehaviorSexual PartnersSubstance Abuse, IntravenousConceptsPre-exposure prophylaxis adherenceSelf-reported PrEP adherenceSex-related risk behaviorsHIV risk reduction behaviorsBio-behavioral interventionPre-exposure prophylaxisProspective clinical trialsHigh-risk peopleHIV prevention interventionsHIV risk behaviorsPilot feasibility studyPost-intervention assessmentPrEP adherenceProphylaxis adherencePreliminary efficacyClinical trialsIntervention groupHIV riskPrevention interventionsRisk behaviorsBio-behavioral approachAdherenceInterventionHigh acceptabilityPrEP
2016
Relapse to opioid use in opioid-dependent individuals released from compulsory drug detention centres compared with those from voluntary methadone treatment centres in Malaysia: a two-arm, prospective observational study
Wegman MP, Altice FL, Kaur S, Rajandaran V, Osornprasop S, Wilson D, Wilson DP, Kamarulzaman A. Relapse to opioid use in opioid-dependent individuals released from compulsory drug detention centres compared with those from voluntary methadone treatment centres in Malaysia: a two-arm, prospective observational study. The Lancet Global Health 2016, 5: e198-e207. PMID: 27964869, PMCID: PMC5657487, DOI: 10.1016/s2214-109x(16)30303-5.Peer-Reviewed Original ResearchConceptsVoluntary drug treatment centresCompulsory drug detention centersOpioid-dependent individualsProspective observational studyOpioid relapseTwo-armObservational studyTreatment centersEvidence-based pharmacological therapyHazard ratio reductionUrinary drug testingDrug testsOpioid agonist treatmentDoris Duke Charitable FoundationOpioid use disorderUrine drug testsMethadone treatment centersAssessed individualsDrug treatment centersNational InstituteEvidence-based treatmentsSubstance use disordersMedical Research CouncilAustralian National HealthVTC participantsAttitudes Toward Addiction, Methadone Treatment, and Recovery Among HIV-Infected Ukrainian Prisoners Who Inject Drugs: Incarceration Effects and Exploration of Mediators
Polonsky M, Rozanova J, Azbel L, Bachireddy C, Izenberg J, Kiriazova T, Dvoryak S, Altice FL. Attitudes Toward Addiction, Methadone Treatment, and Recovery Among HIV-Infected Ukrainian Prisoners Who Inject Drugs: Incarceration Effects and Exploration of Mediators. AIDS And Behavior 2016, 20: 2950-2960. PMID: 27011378, PMCID: PMC5035551, DOI: 10.1007/s10461-016-1375-0.Peer-Reviewed Original ResearchConceptsMethadone maintenance therapyGroup 1Drug useGroup 2 participantsDrug addiction severityAwareness of addictionMaintenance therapyMethadone treatmentExploration of mediatorsHIV stigmaGroup 2MMT treatmentAddiction severityGroup comparisonsDrug addictionHIVHigh rateAddictionHigher optimismDrugsTreatmentParticipantsMethadoneGroupPaper’s key findings
2014
Gender disparities in HIV treatment outcomes following release from jail: results from a multicenter study.
Meyer JP, Zelenev A, Wickersham JA, Williams CT, Teixeira PA, Altice FL. Gender disparities in HIV treatment outcomes following release from jail: results from a multicenter study. American Journal Of Public Health 2014, 104: 434-41. PMID: 24432878, PMCID: PMC3953795, DOI: 10.2105/ajph.2013.301553.Peer-Reviewed Original ResearchConceptsHIV treatment outcomesTreatment outcomesViral suppressionJail detaineesMultisite prospective cohort studyOptimal antiretroviral therapy (ART) adherenceOptimal HIV treatment outcomesWorse HIV treatment outcomesMultiple logistic regression modelAntiretroviral therapy prescriptionHIV primary careHIV clinical careProspective cohort studyAntiretroviral therapy adherenceNon-Hispanic whitesLogistic regression modelsGreater comorbidityCohort studyEvaluable participantsMulticenter studyTherapy adherencePrimary careTherapy prescriptionClinical careHeroin use
2013
Methadone treatment improves tuberculosis treatment among hospitalized opioid dependent patients in Ukraine
Morozova O, Dvoryak S, Altice FL. Methadone treatment improves tuberculosis treatment among hospitalized opioid dependent patients in Ukraine. International Journal Of Drug Policy 2013, 24: e91-e98. PMID: 24360402, PMCID: PMC5553122, DOI: 10.1016/j.drugpo.2013.09.001.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnalgesics, OpioidAntitubercular AgentsDelivery of Health Care, IntegratedDrug UsersFemaleHealth Knowledge, Attitudes, PracticeHeroin DependenceHumansInpatientsMaleMedication AdherenceMethadoneOpiate Substitution TreatmentProspective StudiesRisk FactorsTime FactorsTreatment OutcomeTuberculosisUkraineConceptsTB medication adherenceMethadone maintenanceTB treatmentMedication adherenceTreatment discontinuationMulti-drug resistant tuberculosisInpatient TB treatmentNumerous treatment challengesTB treatment completionOnly independent predictorOpioid-dependent patientsIndependent predictorsPrimary outcomeOpioid dependenceResistant tuberculosisMethadone treatmentTB facilitiesTreatment optionsDependent patientsTuberculosis treatmentTreatment completionTreatment challengesObservational studyMMT groupTreatment retentionFrequent Emergency Department Use Among Released Prisoners With Human Immunodeficiency Virus: Characterization Including a Novel Multimorbidity Index
Meyer JP, Qiu J, Chen NE, Larkin GL, Altice FL. Frequent Emergency Department Use Among Released Prisoners With Human Immunodeficiency Virus: Characterization Including a Novel Multimorbidity Index. Academic Emergency Medicine 2013, 20: 79-88. PMID: 23570481, PMCID: PMC3623800, DOI: 10.1111/acem.12054.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsComorbidityConfidence IntervalsEmergency Service, HospitalFemaleHealth Services MisuseHIV InfectionsHumansIncidenceLongitudinal StudiesMaleMiddle AgedMultivariate AnalysisOdds RatioPoisson DistributionPrisonersProspective StudiesRisk FactorsSeverity of Illness IndexSex FactorsSocioeconomic FactorsUnited StatesVulnerable PopulationsConceptsHuman immunodeficiency virusFrequent ED useFrequent ED usersFrequent emergency department (ED) useEmergency department useED useED usersMultimorbidity indexAntiretroviral therapyED visitsImmunodeficiency virusDischarge planningDepartment useWorse physical health-related qualityPhysical health-related qualityMultivariate Poisson regression modelChronic medical illnessLower physical HRQoLHealth-related qualityPoisson regression modelsPhysical HRQoLMedical illnessPsychiatric illnessPsychiatric correlatesIllness
2012
Correlates of Retention in HIV Care After Release from Jail: Results from a Multi-site Study
Althoff AL, Zelenev A, Meyer JP, Fu J, Brown SE, Vagenas P, Avery AK, Cruzado-Quiñones J, Spaulding AC, Altice FL. Correlates of Retention in HIV Care After Release from Jail: Results from a Multi-site Study. AIDS And Behavior 2012, 17: 156-170. PMID: 23161210, PMCID: PMC3714328, DOI: 10.1007/s10461-012-0372-1.Peer-Reviewed Original ResearchMeSH KeywordsAdultCase ManagementContinuity of Patient CareFemaleFollow-Up StudiesHealth ServicesHealth Services AccessibilityHIV InfectionsHumansMaleMiddle AgedPatient CompliancePatient DischargePrisonersPrisonsProspective StudiesSecondary PreventionSocial SupportSocial WorkSocioeconomic FactorsYoung AdultConceptsCorrelates of retentionHIV careJail detaineesEffective HIV treatmentCase management servicesReceipt of servicesHIV providersClinic visitsHIV treatmentDischarge planningHeroin useHIV educationMulti-site studyChallenging populationTransportation assistanceCarePost-release periodSustained retentionIncarcerated individualsEmpiric dataCorrelatesReleaseHIVPLWHAProvision of educationPost-Release Substance Abuse Outcomes Among HIV-Infected Jail Detainees: Results from a Multisite Study
Krishnan A, Wickersham JA, Chitsaz E, Springer SA, Jordan AO, Zaller N, Altice FL. Post-Release Substance Abuse Outcomes Among HIV-Infected Jail Detainees: Results from a Multisite Study. AIDS And Behavior 2012, 17: 171-180. PMID: 23142854, PMCID: PMC3600070, DOI: 10.1007/s10461-012-0362-3.Peer-Reviewed Original ResearchMeSH KeywordsAdultBehavior, AddictiveFemaleHealth Services AccessibilityHealth Services Needs and DemandHIV InfectionsHumansIll-Housed PersonsInsurance, HealthMaleMiddle AgedMultivariate AnalysisPatient DischargePrevalencePrisonsProspective StudiesSeverity of Illness IndexSocial WorkSocioeconomic FactorsSubstance-Related DisordersTreatment OutcomeYoung AdultConceptsOpioid useJail detaineesPoor health outcomesSubstance use disordersSubstance abuse outcomesSubsequent drug useSubstance abuse treatmentOpioid relapseProspective cohortPsychiatric morbidityAppropriate diagnosisHigh prevalenceComplicate treatmentPsychiatric careUse disordersAlcohol severitySix monthsHealth outcomesDrug useHIVHealthcare accessAbuse treatmentSubstance abuseDrug relapseHealthcare outcomesRetention on Buprenorphine Is Associated with High Levels of Maximal Viral Suppression among HIV-Infected Opioid Dependent Released Prisoners
Springer SA, Qiu J, Saber-Tehrani AS, Altice FL. Retention on Buprenorphine Is Associated with High Levels of Maximal Viral Suppression among HIV-Infected Opioid Dependent Released Prisoners. PLOS ONE 2012, 7: e38335. PMID: 22719814, PMCID: PMC3365007, DOI: 10.1371/journal.pone.0038335.Peer-Reviewed Original ResearchMeSH KeywordsAdultBuprenorphineFemaleHIV InfectionsHumansMaleMiddle AgedNaloxoneOpioid-Related DisordersPrisonersProspective StudiesTreatment OutcomeConceptsMaximum viral suppressionOpioid dependenceViral suppressionGlobal health qualityMaximal viral suppressionHIV treatment outcomesBuprenorphine/naloxoneCopies/mLChronic relapsing diseaseDSM-IV criteriaAntiretroviral therapyOpioid useProspective trialProspective studyRelapsing diseaseOpioid dependentsTreatment outcomesHIV-1HIVNLXHealth qualityTherapyWeeksSuppressionGroupRetention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence
Schwarz R, Zelenev A, Bruce RD, Altice FL. Retention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence. Journal Of Substance Use And Addiction Treatment 2012, 43: 451-457. PMID: 22534003, PMCID: PMC3419304, DOI: 10.1016/j.jsat.2012.03.008.Peer-Reviewed Original ResearchConceptsBuprenorphine maintenance treatmentHealthcare utilizationED utilizationEmergency department usageOpioid-dependent patientsEmergency department utilizationLate-stage diseaseTreatment-seeking patientsBuprenorphine treatmentChart reviewPerson yearsED useMaintenance treatmentOpioid dependenceDependent patientsPrimary careHospitalizationDrug usersNegative binomial regressionBinomial regressionPatientsComparison of timeTreatmentAverage lengthStay
2011
Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community — A potential conduit to improved HIV treatment outcomes
Saber-Tehrani AS, Springer SA, Qiu J, Herme M, Wickersham J, Altice FL. Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community — A potential conduit to improved HIV treatment outcomes. Contemporary Clinical Trials 2011, 33: 436-444. PMID: 22101218, PMCID: PMC3268833, DOI: 10.1016/j.cct.2011.11.002.Peer-Reviewed Original ResearchConceptsHIV treatment outcomesSelf-administered therapyAntiretroviral therapyTreatment outcomesViral loadEvidence-based adherence interventionsPoor HIV treatment outcomesGenotypic resistance testingMedication-assisted treatmentDSM-IV criteriaAlcohol use disorderCase management servicesViral suppressionPrimary outcomeOpioid dependenceAdherence interventionsCD4 testingIntervention periodStudy groupEligibility criteriaUse disordersIntervention monthDrug usersAdverse HIVHIVDrug Treatment Outcomes Among HIV-Infected Opioid-Dependent Patients Receiving Buprenorphine/Naloxone
Fiellin DA, Weiss L, Botsko M, Egan JE, Altice FL, Bazerman LB, Chaudhry A, Cunningham CO, Gourevitch MN, Lum PJ, Sullivan LE, Schottenfeld RS, O'Connor PG. Drug Treatment Outcomes Among HIV-Infected Opioid-Dependent Patients Receiving Buprenorphine/Naloxone. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s33-s38. PMID: 21317592, PMCID: PMC3863630, DOI: 10.1097/qai.0b013e3182097537.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxoneBuprenorphine/naloxone treatmentOpioid-dependent patientsDrug useOpioid useNaloxone treatmentHIV treatment settingsIllicit opioid useOngoing drug useDrug treatment outcomesNaloxone dosesIllicit opioidsOpioid dependenceOffice visitsProspective studyHIV treatmentRetained patientsTreatment outcomesTreatment retentionPatientsTreatment settingsAddiction treatment processNaloxoneTreatment populationHIV
2009
A Prospective Controlled Trial of Routine Opt-Out HIV Testing in a Men's Jail
Kavasery R, Maru DS, Sylla LN, Smith D, Altice FL. A Prospective Controlled Trial of Routine Opt-Out HIV Testing in a Men's Jail. PLOS ONE 2009, 4: e8056. PMID: 19946371, PMCID: PMC2777336, DOI: 10.1371/journal.pone.0008056.Peer-Reviewed Original ResearchConceptsRoutine optHIV testingProspective Controlled TrialTesting groupMen's jailProportion of menPreliminary positive resultsPrimary outcomeControlled TrialsJail detaineesMultivariate analysisDisease controlHIVLower likelihoodWeek periodHigh ratePositive resultsTrialsGroupMale inmatesNew HavenOptimal timeJailEarly releaseTestingRoutine Opt-Out HIV Testing Strategies in a Female Jail Setting: A Prospective Controlled Trial
Kavasery R, Maru DS, Cornman-Homonoff J, Sylla LN, Smith D, Altice FL. Routine Opt-Out HIV Testing Strategies in a Female Jail Setting: A Prospective Controlled Trial. PLOS ONE 2009, 4: e7648. PMID: 19946370, PMCID: PMC2777332, DOI: 10.1371/journal.pone.0007648.Peer-Reviewed Original ResearchConceptsRoutine optHIV testingJail settingsNew CDC guidelinesHIV testing strategiesProspective Controlled TrialLow testing ratesProportion of womenControlled TrialsPrimary outcomeCDC guidelinesHigh prevalenceTesting ratesJail detaineesYounger ageLower likelihoodHIVWeek periodHigh rateTesting groupTrialsWomenTesting strategiesFemale inmatesGroup
2007
Directly Administered Antiretroviral Therapy for HIV-Infected Drug Users Does Not Have an Impact on Antiretroviral Resistance
Maru DS, Kozal MJ, Bruce RD, Springer SA, Altice FL. Directly Administered Antiretroviral Therapy for HIV-Infected Drug Users Does Not Have an Impact on Antiretroviral Resistance. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2007, 46: 555-563. PMID: 18193497, PMCID: PMC2684061, DOI: 10.1097/qai.0b013e318158c0bd.Peer-Reviewed Original ResearchConceptsDrug resistance mutationsNew drug resistance mutationsSelf-administered therapyDrug usersAntiretroviral therapyHIV genotypic resistance testingFuture drug optionsAntiretroviral drug resistanceGenotypic resistance testingGenotypic sensitivity scoreMain outcome measuresMedication resistanceModified intentionVirologic benefitAntiretroviral resistanceTreat analysisClinical outcomesDrug mutationsDrug optionsOutcome measuresAdjusted probabilityDrug resistanceResistance mutationsHIVEffective interventionsSuperiority of Directly Administered Antiretroviral Therapy over Self-Administered Therapy among HIV-Infected Drug Users: A Prospective, Randomized, Controlled Trial
Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of Directly Administered Antiretroviral Therapy over Self-Administered Therapy among HIV-Infected Drug Users: A Prospective, Randomized, Controlled Trial. Clinical Infectious Diseases 2007, 45: 770-778. PMID: 17712763, PMCID: PMC2693907, DOI: 10.1086/521166.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsSelf-administered therapyT-lymphocyte countsDrug usersAntiretroviral therapyLymphocyte countRNA levelsPrimary outcomeProportion of patientsGreater mean reductionHIV treatment programsLog10 copies/Human immunodeficiency virusCopies/mLDAART groupVirologic outcomesSecondary outcomesControlled TrialsImmunodeficiency virusPoor adherenceTreatment adherenceEntry criteriaTreat approachCopies/Mean change